Recce Pharmaceuticals Receives ‘intent to grant’ Patent Family 4 for anti-infectives
- Recce Pharmaceuticals (RCE) receives boost from the Australian Patent Office after announcing its ‘intent to grant’ the first of Recce’s new Patent Family 4 for anti-infectives
- The patent covers the “Process for Preparation of Biologically Active Copolymer”, with an expiry date set for 2041
- The Family 4 patent relates to Recce 327 (R327) and Recce 529 (R529) and covers the process for the preparation of Recce anti-infectives as well as the use of R327/R529 for the treatment of disease
- Recce confirmed Patent Cooperation Treaty Country (PCT) patent submissions are in respective stages of review
- RCE shares are up 1.74 per cent and trading at 58.5 cents at 1:16 pm AEST
